Literature DB >> 11863332

Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study.

M Birrer1, D D Do, F Mahler, J Triller, I Baumgartner.   

Abstract

OBJECTIVES: to assess restenosis rates and blood pressure response after percutaneous transluminal renal angioplasty (PTRA) in patients treated for fibromuscular dysplastic renal artery stenosis.
METHODS: a prospective 12-month follow-up study of 27 patients with 31 treated renal artery stenosis. Follow-up assessment included colour-coded duplex sonography (CCD) of renal arteries, monitoring of blood pressure, antihypertensive medication, and creatinine measurements before discharge and at 3, 6, and 12 months. Primary end point was defined as a haemodynamically significant restenosis >60% assessed by CCD.
RESULTS: there was a cumulative 23% restenosis rate at 12 months. Arterial hypertension was cured or improved in 93% of patients immediately after the intervention and remained cured/improved in 74% of patients at 12 months of follow-up. Renal failure present in five patients before PTRA stabilised or improved in all patients.
CONCLUSION: although restenosis rate after PTRA in fibromuscular dysplasia is as high as in non-ostial atherosclerotic lesions, there remains a considerable higher therapeutic effect. Profound pressure response and recurrent arterial hypertension with restenosis support the high probability of a renovascular origin of arterial hypertension in this young and otherwise healthy population compared to patients with atherosclerotic renal artery lesions. Copyright 2002 Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11863332     DOI: 10.1053/ejvs.2001.1559

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  20 in total

1.  Current opinions in renovascular hypertension.

Authors:  Ankit N Mehta; Andrew Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-07

2.  Fibromuscular dysplasia presenting as a renal infarction: a case report.

Authors:  Annelies Van den Driessche; Erik Van Hul; Malika Ichiche; Gert A Verpooten; Jean-Louis Bosmans
Journal:  J Med Case Rep       Date:  2010-06-30

Review 3.  An update on renovascular hypertension.

Authors:  Martin Senitko; Andrew Z Fenves
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

Review 4.  Renovascular hypertension and ischemic nephropathy.

Authors:  Stephen C Textor; Lilach Lerman
Journal:  Am J Hypertens       Date:  2010-09-23       Impact factor: 2.689

5.  Fibromuscular Dysplasia.

Authors:  David P Slovut; Jeffrey W Olin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-06

6.  Revascularization of swine renal artery stenosis improves renal function but not the changes in vascular structure.

Authors:  Frederic Favreau; Xiang-Yang Zhu; James D Krier; Jing Lin; Lizette Warner; Stephen C Textor; Lilach O Lerman
Journal:  Kidney Int       Date:  2010-05-12       Impact factor: 10.612

7.  Interventional management of renal vascular origin hematuria.

Authors:  Gregory J Dubel; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2007-03       Impact factor: 1.513

Review 8.  Challenges in the diagnosis and management of renal artery stenosis.

Authors:  Moro O Salifu; Dhiren M Haria; Olurotimi Badero; Serhat Aytug; Samy I McFarlane
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

9.  Percutaneous renal artery angioplasty and stenting: indications, technique and results.

Authors:  H K Kok; S Leong; P Govender; R Browne; W C Torreggiani
Journal:  Ir J Med Sci       Date:  2012-12-04       Impact factor: 1.568

Review 10.  Treatment of severe renal artery stenosis by percutaneous transluminal renal angioplasty and stent implantation: review of the pediatric experience: apropos of two cases.

Authors:  Kai König; Jutta Gellermann; Uwe Querfeld; Martin B E Schneider
Journal:  Pediatr Nephrol       Date:  2006-03-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.